Angelini Ventures
Advancing neuroscience: Angelini Ventures invests in Neumirna’s innovative RNA therapeutics
Angelini Ventures is proud to announce its role as co-lead investor in a €20 million Series A financing round for Neumirna Therapeutics, a cutting-edge biotech company revolutionizing the treatment of neurological disorders with RNA-based therapies. This funding, co-led alongside Invivo Partners and supported by Innovestor’s Life Science Fund and other key investors, will enable Neumirna to advance the clinical development of its lead candidate, NMT.001.
NMT.001 is a potential disease-modifying Antisense Oligonucleotide (ASO) therapy targeting drug-resistant epilepsy (DRE), a condition that impacts millions of patients worldwide. Additionally, the funding will expand Neumirna's R&D capabilities and scale its pioneering RNA therapeutics platform to address other complex neurological diseases, including Parkinson’s.
As co-lead investors, we are proud to support Neumirna in its mission to harness the potential of RNA therapies to tackle epilepsy and other complex neurological disorders. By leveraging microRNA-targeted drugs to address the underlying causes of diseases like epilepsy and Parkinson’s disease, Neumirna is breaking new ground in the field.
Thomas Thestrup,
Founded in 2020 by Dr. Henrik Klitgaard, Prof. Sakari Kauppinen, and Lars Hellerung Christiansen, Neumirna is a prime example of the transformative science that Angelini Ventures is committed to supporting.
This investment marks Angelini Ventures’ fifth in the field of neuroscience and reaffirms its dedication to supporting transformative science in brain health.
Explore more about this milestone and its impact on neuroscience innovation in the full press release: